[1]
|
Roth, G.A., Mensah, G.A., Johnson, C.O., et al. (2020) Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update from the GBD 2019 Study. Journal of the American College of Cardiology, 76, 2982-3021.
https://doi.org/10.1016/j.jacc.2020.11.010
|
[2]
|
中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2021概要[J]. 心脑血管病防治, 2022, 22(4): 20-36+40.
|
[3]
|
北京心脏学会. 脂蛋白(a)与心血管疾病风险关系及临床管理的专家科学建议[J]. 中国循环杂志, 2021, 36(12): 1158-1167.
|
[4]
|
Tsimikas, S., Fazio, S., Ferdinand, K.C., et al. (2018) NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascu-lar Disease and Aortic Stenosis. Journal of the American College of Cardiology, 71, 177-192. https://doi.org/10.1016/j.jacc.2017.11.014
|
[5]
|
Orsó, E. and Schmitz, G. (2017) Lipoprotein(a) and Its Role in In-flammation, Atherosclerosis and Malignancies. Clinical Research in Cardiology Supplements, 12, 31-37. https://doi.org/10.1007/s11789-017-0084-1
|
[6]
|
Kronenberg, F., Mora, S., Stroes, E.S.G., et al. (2022) Lipopro-tein(a) in Atherosclerotic Cardiovascular Disease and Aortic Stenosis: A European Atherosclerosis Society Consensus Statement. European Heart Journal, 43, 3925-3946.
|
[7]
|
石惠薇, 热娜提•肉孜, 刘硕霖, 吴娜琼. 高脂蛋白a血症的相关治疗进展[J]. 心血管病学进展, 2021, 42(4): 297-301.
|
[8]
|
林振南, 贾砚慧, 陈恕凤. 脂蛋白(a)基因多态性与冠心病相关性的Meta分析[J]. 中国动脉硬化杂志, 2022, 30(2): 152-160.
|
[9]
|
Wilson, D.P., Jacobson, T.A., Jones, P.H., et al. (2022) Use of Lipoprotein(a) in Clinical Practice: A Biomarker Whose Time Has Come. A Scientific Statement from the National Lipid Association. Journal of Clinical Lipidology, 13, 374-392.
https://doi.org/10.1016/j.jacl.2019.04.010
|
[10]
|
Liu, T., Yoon, W.-S. and Lee, S.-R. (2021) Recent Updates of Lip-oprotein(a) and Cardiovascular Disease. Chonnam Medical Journal, 57, 36-43. https://doi.org/10.4068/cmj.2021.57.1.36
|
[11]
|
Tsimikas, S. (2017) A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. Journal of the American College of Cardiology, 69, 692-711. https://doi.org/10.1016/j.jacc.2016.11.042
|
[12]
|
Enas, E.A., Varkey, B., Dharmarajan, T.S., Pare, G. and Bahl, V.K. (2019) Lipoprotein(a): AN Independent, Genetic, and Causal Factor for Cardiovascular Disease and Acute Myocardial Infarction. Indian Heart Journal, 71, 99-112.
https://doi.org/10.1016/j.ihj.2019.03.004
|
[13]
|
Niccoli, G., Cin, D., Scalone, G., et al. (2016) Lipoprotein(a) Is Re-lated to Coronary Atherosclerotic Burden and a Vulnerable Plaque Phenotype in Angiographically Obstructive Coronary Artery Disease. Atherosclerosis, 246, 214-220.
https://doi.org/10.1016/j.atherosclerosis.2016.01.020
|
[14]
|
Niccoli, G., Chin, D., Scalone, G., et al. (2016) Data on the Lipoprotein(a), Coronary Atherosclerotic Burden and Vulnerable Plaque Phenotype in Angiographic Obstructive Coronary Artery Disease. Data in Brief, 7, 1409-1412.
https://doi.org/10.1016/j.dib.2016.04.017
|
[15]
|
Kaiser, Y., Daghem, M., Tzolos, E., et al. (2022) Association of Lipoprotein(a) with Atherosclerotic Plaque Progression. Journal of the American College of Cardiology, 79, 223-233. https://doi.org/10.1016/j.jacc.2021.10.044
|
[16]
|
Sumarjaya, I., Nadha, I.K.B. and Lestari, A.A.W. (2020) High Lipoprotein(a) Levels as a Predictor of Major Adverse Cardiovascular Events in Hospitalized-Acute Myocardial Infarc-tion Patients. Vascular Health and Risk Management, 16, 125-132. https://doi.org/10.2147/VHRM.S233503
|
[17]
|
Hoursalas, A., Tsarouhas, K., Tsitsimpikou, C., et al. (2022) Mod-erately Elevated Lipoprotein(a) Levels Are Associated with an Earlier Need for Percutaneous Coronary Intervention in Recurrent Cardiovascular Disease. Experimental and Therapeutic Medicine, 24, Article No. 444. https://doi.org/10.3892/etm.2022.11371
|
[18]
|
Xue, Y., Jian, S., Zhou, W., et al. (2021) Associations of Lipopro-tein(a) with Coronary Atherosclerotic Burden and All-Cause Mortality in Patients with ST-Segment Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention. Frontiers in Cardiovascular Medicine, 8, Article 638679.
https://doi.org/10.3389/fcvm.2021.638679
|
[19]
|
Rallidis, L.S., Pavlakis, G., Foscolou, A., et al. (2018) High Levels of Lipoprotein(a) and Premature Acute Coronary Syndrome. Atherosclerosis, 269, 29-34. https://doi.org/10.1016/j.atherosclerosis.2017.12.011
|
[20]
|
Chen, Z., Jiang, C., Qu, H., et al. (2019) Association of Lipoprotein(a) and Major Adverse Cardiovascular Events in Patients with Percutaneous Coronary Intervention. Archives of Medical Science, 15, 1375-1380.
https://doi.org/10.5114/aoms.2018.79401
|
[21]
|
李新健, 徐昕晔, 王贵松. 血流储备分数用于指导急性ST段抬高型心肌梗死患者非梗死相关血管血运重建的研究进展[J]. 中国介入心脏病学杂志, 2022, 30(5): 378-381.
|
[22]
|
赵振燕, 宋光远, 吴永健. 脂蛋白(a)与钙化性主动脉瓣狭窄的关系[J]. 中国循环杂志, 2021, 36(9): 920-923.
|
[23]
|
Zheng, K.H., Arsenault, B.J., Kaiser, Y., et al. (2019) ApoB/apoA-I Ratio and Lp(a) Associations with Aortic Valve Stenosis Incidence: Insights From the EPIC-Norfolk Prospective Population Study. Journal of the Ameri-can Heart Association, 8, e013020. https://doi.org/10.1161/JAHA.119.013020
|
[24]
|
Liu, Q., Yu, Y., Xi, R., et al. (2022) Association between Lipoprotein(a) and Calcific Aortic Valve Disease: A Systematic Review and Meta-Analysis. Frontiers in Cardiovascular Medicine, 9, Article 877140.
https://doi.org/10.3389/fcvm.2022.877140
|
[25]
|
Liu, S.L., Rozi, R., Shi, H.-W., et al. (2020) Association of Serum Lipoprotein(a) Level with the Severity and Prognosis of Calcific Aortic Valve Stenosis: A Chinese Cohort Study. Jour-nal of Geriatric Cardiology, 17, 133-140.
|
[26]
|
Jang, A.Y., Han, S.H., Sohn, I.S., Oh, P.C. and Koh, K.K. (2020) Lip-oprotein(a) and Cardiovascular Diseases—Revisited. Circulation Journal, 84, 867-874. https://doi.org/10.1253/circj.CJ-20-0051
|
[27]
|
Tsimikas, S., Gordts, P., Nora, C., Yeang, C. and Witztum, J.L. (2020) Statin Therapy Increases Lipoprotein(a) Levels. European Heart Journal, 41, 2275-2284. https://doi.org/10.1093/eurheartj/ehz310
|
[28]
|
Lincoff, A.M., Nicholls, S.J., Riesmeyer, J.S., et al. (2017) Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. New England Journal of Medicine, 376, 1933-1942. https://doi.org/10.1056/NEJMoa1609581
|
[29]
|
Farmakis, I., Doundoulakis, I., Pagiantza, A., et al. (2021) Lipoprotein(a) Reduction with Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-Analysis. Journal of Cardiovascular Pharmacology, 77, 397-407. https://doi.org/10.1097/FJC.0000000000000963
|
[30]
|
Mach, F., Baigent, C., Catapano, A.L., et al. (2020) 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk. Euro-pean Heart Journal, 41, 111-188.
https://doi.org/10.1093/eurheartj/ehz455
|
[31]
|
Warden, B.A. and Duell, P.B. (2021) Inclisiran: A Novel Agent for Lowering Apolipoprotein B-Containing Lipoproteins. Journal of Cardiovascular Pharmacology, 78, e157-e174. https://doi.org/10.1097/FJC.0000000000001053
|
[32]
|
杨冬梅, 潘彦, 白文伟. 载脂蛋白B合成抑制剂治疗血脂异常的有效性与安全性的Meta分析[J]. 心肺血管病杂志, 2017, 36(10): 858-863.
|
[33]
|
Swerdlow, D.I., Rider, D.A., Yavari, A., et al. (2022) Treatment and Prevention of Lipoprotein(a)-Mediated Cardiovascular Disease: The Emerging Potential of RNA Interference Therapeutics. Cardiovascular Research, 118, 1218-1231.
https://doi.org/10.1093/cvr/cvab100
|
[34]
|
赵量, 高莹, 刘庚, 等. 血脂净化治疗家族性高胆固醇血症的单中心研究[J]. 中华心血管病杂志, 2022, 50(6): 585-590.
|